1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
暂无分享，去创建一个
A. Mansfield | G. Curigliano | M. Brose | B. Keam | G. Lopes | L. Wirth | I. Matos | S. Leboulleux | V. Subbiah | C. Baik | D. Sarker | C. Turner | Y. Godbert | D. Adkins | C. Lin | M. Hu | H. Zhang | V. Zhu | M. Taylor | M. Schuler | Lori J. Wirth | Marcia S. Brose | Sophie Leboulleux | Viola W. Zhu | Christina S. Baik | Yann Godbert